Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ventricular tachycardia

Ventricular tachycardia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ventricular tachycardia

42 trials tracked for Ventricular tachycardia: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 369 citations.

42Trials tracked
9Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 7 Phase 3 2 Phase 2 1 Phase 1 1 Other / NA 31
  1. Phase 3 Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation Completed · 369 cited
  2. Phase 3 A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias. Completed · 1 cited
  3. Phase 4 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation Completed
  4. Phase 4 ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed
  5. Phase 4 The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock Completed
  6. Phase 4 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia Completed
Show 36 more trials
  1. Phase 4 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia Completed
  2. Phase 4 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed
  3. Phase 4 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia Completed
  4. Phase 2 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia Completed
  5. Phase 1 Automatic External Defibrillation Monitoring in Cardiac Arrest Completed
  6. N/A Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead Completed
  7. N/A Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction Completed
  8. N/A Bipolar Ventricular Tachycardia (VT) Study Completed
  9. N/A Tachy Prediction Download Study Completed
  10. N/A Shockless Implant Evaluation Completed
  11. N/A AVAI: Atrial Ventricular Arrythmia Incidence Completed
  12. N/A Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. Completed
  13. N/A Physiologic Pacing Registry Completed
  14. N/A Imaging With a Radio Tracer to Guide VT Ablations Completed
  15. N/A Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping Completed
  16. N/A A Study Assessing Arrhythmia Mapping With the Multi-Electrode OPTRELL™ Mapping Catheter Completed
  17. N/A Ablation at Virtual-hEart pRedicted Targets for VT Completed
  18. N/A S-ICD® System IDE Clinical Study Completed
  19. N/A Contrast ICE for Myocardial Scar in VT Ablations Completed
  20. N/A Introductory Clinical Trial for Measuring Patients Before, During, and After an Electrophysiology (EP) Procedure With a Novel, Body-Worn Sensor Completed
  21. N/A Boston Scientific Post Market Subcutaneous-Implantable Cardioverter Defibrillator (S-ICD) Registry Completed
  22. N/A Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia Completed
  23. N/A Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation Completed
  24. N/A Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia Completed
  25. N/A REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients Completed
  26. N/A A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter Completed
  27. N/A DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study Completed
  28. N/A Assessment of the Sphere-9™ Catheter and Affera Mapping and Ablation System for Treatment of Atrial and Ventricular Arrhythmias Completed
  29. N/A Magnetic Stimulation to Treat VT Storm Completed
  30. N/A REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation Completed
  31. N/A Advisor HD Grid Observational Study Completed
  32. N/A An Assessment of Dual Site Left Ventricular Endocardial Pacing Completed
  33. N/A Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies Completed
  34. N/A Vest Prevention of Early Sudden Death Trial and VEST Registry Completed
  35. N/A A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter Completed
  36. N/A Multimodality Assessment of Ventricular Scar Arrhythmogenicity. Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Ventricular tachycardia: what the trials found

In established evidence for ventricular tachycardia, catheter ablation with the NAVISTAR® THERMOCOOL® Catheter achieved acute success in 74.9% of subjects, with all-cause mortality of 13.3% within 12 months and cardiovascular-specific adverse events in 4.3% within seven days of the procedure 4. Magnetic irrigated ablation catheter use resulted in 62% of participants being free from VT at 1 year post-treatment 2.

For device-based management, dual chamber ICDs were associated with 1 inappropriate shock in each of two comparison groups (p=1.0), 31 appropriate shocks versus 1 (p=0.050), and 37 versus 0 atrial tachyarrhythmia episodes lasting over 5 minutes 5. Two additional trials of implantable cardiac defibrillators reported no outcome results 67.

Among pharmacological and other interventions, DOAC use showed transient ischemic attack in 6 versus 22 participants (p=0.001), asymptomatic cerebral events on MRI at 24 hours in 15 versus 28, and at 30 days in 8 versus 22 1. Remifentanil sedation achieved PVC suppression in 2 participants (p=0.05) 3. Ethanol treatment resulted in 60 versus 91 treated subjects with freedom from symptomatic post-procedural AF or flutter at 12 and 15 months 8. Dantrolene/Ryanodex was studied without reported outcome results 9.

Recent results — preliminary, needs further review

  • Virtual Heart Guided Ablation was evaluated in a recent trial, but no outcome results were reported 12.

For the clinician treating this condition

  • Catheter ablation for VT can achieve acute success in about three-quarters of patients, with a 1-year freedom from VT of 62% using a magnetic irrigated catheter 24.
  • Dual chamber ICDs may reduce appropriate shocks compared to a comparator, but inappropriate shock rates were similar between groups 5.
  • DOAC therapy was associated with fewer transient ischemic attacks and asymptomatic cerebral events compared to a comparator 1.
  • Remifentanil sedation and ethanol treatment showed some effects on PVC suppression and freedom from atrial arrhythmias, respectively, but these findings are from small or specific populations 38.

AI synthesis of 10 cited trials, updated Sep 16, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Retrograde PVC ablation can cause rare but serious iatrogenic left main coronary artery dissection
Cardiology Guideline
Retrograde PVC ablation can cause rare but serious iatrogenic left main coronary artery dissection Rare heart complication occurs during procedure to treat heart rhythm
This case report describes a 60-year-old man with medication-refractory monomorphic PVCs who experienced an iatrogenic LMCA dissection durin…
A rare complication during a heart rhythm procedure highlights the need for quick action and specialized teams when complications arise.
Frontiers Sep 15, 2026